Tourmaline Bio, Inc. (TRML)
NASDAQ: TRML · Real-Time Price · USD
21.13
+0.79 (3.88%)
Dec 20, 2024, 1:54 PM EST - Market open
Tourmaline Bio Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Tourmaline Bio stock have an average target of 54, with a low estimate of 25 and a high estimate of 74. The average target predicts an increase of 155.56% from the current stock price of 21.13.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Tourmaline Bio stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 3 | 4 |
| Buy | 1 | 1 | 1 | 1 | 0 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 3 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Guggenheim | Guggenheim | Strong Buy Reiterates n/a | Strong Buy | Reiterates | n/a | n/a | Dec 11, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $25 | Buy | Reiterates | $25 | +18.32% | Dec 11, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $49 | Strong Buy | Reiterates | $49 | +131.90% | Dec 11, 2024 |
| BMO Capital | BMO Capital | Buy Initiates $50 | Buy | Initiates | $50 | +136.63% | Dec 6, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $48 → $49 | Strong Buy | Maintains | $48 → $49 | +131.90% | Nov 11, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
8.74M
EPS This Year
-3.03
from -8.87
EPS Next Year
-3.69
from -3.03
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | n/a | 63.0M | 63.0M | |||
| Avg | n/a | 8.7M | 10.2M | |||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | 620.6% | |||
| Avg | - | - | 16.7% | |||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -2.95 | -1.88 | -3.98 | |||
| Avg | -3.03 | -3.69 | -4.87 | |||
| Low | -3.51 | -4.49 | -5.86 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.